RXRX
Recursion Pharmaceuticals, Inc.
Price Chart
Latest Quote
$3.23
+0.12 (+3.86%)
Current Price
| Previous Close | $3.11 |
| Open | $3.18 |
| Day High | $3.28 |
| Day Low | $3.11 |
| Volume | 22,407,988 |
Stock Information
| Shares Outstanding | 524.68M |
| Total Debt | $72.38M |
| Cash Equivalents | $654.47M |
| Revenue | $66.41M |
| Net Income | $-559.78M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.71B |
| EPS (TTM) | $-1.16 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.13B |
| Sales | $66.41M |
| Income | $-559.78M |
| Book/sh | $1.93 |
| Cash/sh | $1.25 |
| Employees | 600 |
Financial Ratios
| Quick Ratio | 5.15 |
| Current Ratio | 5.47 |
| Debt/Eq | 7.06 |
Returns & Margins
| ROA | -27.66% |
| ROE | -57.16% |
| Operating Margin | -1985.55% |
Ownership
| Insider Ownership | 2.26% |
| Institutional Ownership | 68.78% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.68 |
| P/S | 25.82 |
| P/B | 1.67 |
Analyst Data
| Recommendation | none |
| Target Price | $6.64 |
Technical Indicators
| SMA20 | $3.30 |
| SMA50 | $3.33 |
| SMA200 | $4.15 |
| RSI | 41.71 |
| ATR | 0.2893 |
| Shares Float | 513.08M |
| Short Float | 32.82% |
| Short Ratio | 9.90 |
| Volatility | 1.00 |
| Rel Volume | 1.12 |
Performance History
| Week | +2.54% |
| Month | +13.33% |
| Quarter | -4.15% |
| 6 Months | -23.10% |
| YTD | -23.10% |
| Year | -33.26% |
| 3 Years | -67.51% |
| 5 Years | -89.66% |
| 10 Years | -89.68% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $3.23 | 24,853,700 |
| 2026-06-17 | $3.11 | 22,173,100 |
| 2026-06-16 | $3.18 | 15,477,000 |
| 2026-06-15 | $3.29 | 15,393,600 |
| 2026-06-12 | $3.15 | 14,804,700 |
| 2026-06-11 | $3.15 | 25,424,800 |
| 2026-06-10 | $3.04 | 19,534,900 |
| 2026-06-09 | $3.22 | 17,850,900 |
| 2026-06-08 | $3.32 | 15,796,600 |
| 2026-06-05 | $3.32 | 26,943,900 |
| 2026-06-04 | $3.80 | 38,926,300 |
| 2026-06-03 | $3.47 | 18,499,200 |
| 2026-06-02 | $3.61 | 20,861,600 |
| 2026-06-01 | $3.79 | 30,989,100 |
| 2026-05-29 | $3.59 | 29,983,600 |
| 2026-05-28 | $3.44 | 24,723,300 |
| 2026-05-27 | $3.17 | 26,463,000 |
| 2026-05-26 | $2.97 | 29,619,800 |
| 2026-05-22 | $3.01 | 14,023,400 |
| 2026-05-21 | $3.11 | 13,174,300 |
| 2026-05-20 | $2.96 | 13,162,500 |
| 2026-05-19 | $2.85 | 16,011,100 |
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
đ° Latest News
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Zacks âĸ 2026-06-16T21:50:03Z
X-Energy (XE) Powers 13.5% as Cathie Wood Gobbles More Stake
Insider Monkey âĸ 2026-06-16T02:34:59Z
Cathie Wood Buys $444 Million in SpaceX, Dumps Tesla and AMD
GuruFocus.com âĸ 2026-06-15T18:48:08ZRecursion Pharmaceuticals (RXRX) Stock Valuation After AI Drug Discovery And REC-1245 REC-4881 Updates
Simply Wall St. âĸ 2026-06-13T18:10:02Z
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
Zacks âĸ 2026-06-12T15:30:02Z
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Zacks âĸ 2026-06-10T21:50:05Z
Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?
Zacks âĸ 2026-06-05T15:30:28Z
Recursion (RXRX) Climbs 9.5% Ahead of Next Weekâs Business Updates
Insider Monkey âĸ 2026-06-05T01:15:12Z
Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 Results
Simply Wall St. âĸ 2026-06-04T13:14:22Z
Recursionâs AI Drug Pipeline Progress Tests Investor Patience And Valuation
Simply Wall St. âĸ 2026-06-04T07:08:32Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $70,953,000 | $45,238,000 | $42,587,000 | $48,275,000 |
| Cost Of Revenue | $70,953,000 | $45,238,000 | $42,587,000 | $48,275,000 |
| Total Revenue | $74,256,000 | $58,488,000 | $43,876,000 | $39,681,000 |
| Operating Revenue | $74,256,000 | $58,488,000 | $43,876,000 | $39,681,000 |
| Expenses | ||||
| Interest Expense | $1,810,000 | $1,572,000 | $97,000 | $55,000 |
| Total Expenses | $722,388,000 | $537,492,000 | $393,936,000 | $285,408,000 |
| Other Income Expense | $-17,741,000 | $30,000 | $-1,087,000 | $52,000 |
| Other Non Operating Income Expenses | $-17,741,000 | $30,000 | $-1,087,000 | $52,000 |
| Net Non Operating Interest Income Expense | $20,978,000 | $14,186,000 | $19,019,000 | $6,199,000 |
| Interest Expense Non Operating | $1,810,000 | $1,572,000 | $97,000 | $55,000 |
| Operating Expense | $651,435,000 | $492,254,000 | $351,349,000 | $237,133,000 |
| Other Operating Expenses | $-425,000 | $-351,000 | $-699,000 | $-162,000 |
| General And Administrative Expense | $176,589,000 | $178,184,000 | $110,822,000 | $81,599,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-644,759,000 | $-463,661,000 | $-328,066,000 | $-239,476,000 |
| Net Interest Income | $20,978,000 | $14,186,000 | $19,019,000 | $6,199,000 |
| Interest Income | $22,788,000 | $15,758,000 | $19,116,000 | $6,254,000 |
| Normalized Income | $-644,759,000 | $-463,661,000 | $-328,066,000 | $-239,476,000 |
| Net Income From Continuing And Discontinued Operation | $-644,759,000 | $-463,661,000 | $-328,066,000 | $-239,476,000 |
| Total Operating Income As Reported | $-648,132,000 | $-479,004,000 | $-350,060,000 | $-245,727,000 |
| Net Income Common Stockholders | $-644,759,000 | $-463,661,000 | $-328,066,000 | $-239,476,000 |
| Net Income | $-644,759,000 | $-463,661,000 | $-328,066,000 | $-239,476,000 |
| Net Income Including Noncontrolling Interests | $-644,759,000 | $-463,661,000 | $-328,066,000 | $-239,476,000 |
| Net Income Continuous Operations | $-644,759,000 | $-463,661,000 | $-328,066,000 | $-239,476,000 |
| Pretax Income | $-644,895,000 | $-464,788,000 | $-332,128,000 | $-239,476,000 |
| Interest Income Non Operating | $22,788,000 | $15,758,000 | $19,116,000 | $6,254,000 |
| Operating Income | $-648,132,000 | $-479,004,000 | $-350,060,000 | $-245,727,000 |
| Gross Profit | $3,303,000 | $13,250,000 | $1,289,000 | $-8,594,000 |
| Special Income Charges | - | - | $0 | $0 |
| Per Share | ||||
| Diluted EPS | $-1.44 | $-1.69 | $-1.58 | $-1.36 |
| Basic EPS | $-1.44 | $-1.69 | $-1.58 | $-1.36 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-559,384,000 | $-426,722,000 | $-307,629,000 | $-227,665,000 |
| Reconciled Depreciation | $83,701,000 | $36,494,000 | $24,402,000 | $11,756,000 |
| EBITDA (Bullshit earnings) | $-559,384,000 | $-426,722,000 | $-307,629,000 | $-227,665,000 |
| EBIT | $-643,085,000 | $-463,216,000 | $-332,031,000 | $-239,421,000 |
| Diluted Average Shares | $447,446,109 | $274,207,146 | $207,853,702 | $175,537,487 |
| Basic Average Shares | $447,446,109 | $274,207,146 | $207,853,702 | $175,537,487 |
| Diluted NI Availto Com Stockholders | $-644,759,000 | $-463,661,000 | $-328,066,000 | $-239,476,000 |
| Tax Provision | $-136,000 | $-1,127,000 | $-4,062,000 | $0 |
| Research And Development | $475,271,000 | $314,421,000 | $241,226,000 | $155,696,000 |
| Selling General And Administration | $176,589,000 | $178,184,000 | $110,822,000 | $81,599,000 |
| Other Gand A | $176,589,000 | $178,184,000 | $110,822,000 | $81,599,000 |
| Total Unusual Items | - | - | $0 | $0 |
| Total Unusual Items Excluding Goodwill | - | - | $0 | $0 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $658,804,000 | $550,054,000 | $374,937,000 | $483,699,000 |
| Total Assets | $1,474,130,000 | $1,448,598,000 | $653,699,000 | $701,288,000 |
| Total Non Current Assets | $661,285,000 | $734,329,000 | $215,562,000 | $131,474,000 |
| Other Non Current Assets | $18,787,000 | $14,454,000 | $6,890,000 | $7,920,000 |
| Non Current Deferred Assets | $957,000 | $1,934,000 | $0 | - |
| Non Current Deferred Taxes Assets | $957,000 | $1,934,000 | $0 | - |
| Goodwill And Other Intangible Assets | $472,061,000 | $484,728,000 | $88,499,000 | $2,107,000 |
| Other Intangible Assets | $309,903,000 | $335,855,000 | $36,443,000 | $1,306,000 |
| Current Assets | $812,845,000 | $714,269,000 | $438,137,000 | $569,814,000 |
| Other Current Assets | $28,566,000 | $38,107,000 | $40,247,000 | $15,869,000 |
| Restricted Cash | $4,594,000 | $3,045,000 | $3,231,000 | $1,280,000 |
| Prepaid Assets | $11,742,000 | $29,601,000 | - | - |
| Receivables | $24,649,000 | $49,166,000 | $3,094,000 | $2,753,000 |
| Other Receivables | $24,649,000 | $49,166,000 | $3,094,000 | $2,753,000 |
| Cash Cash Equivalents And Short Term Investments | $743,294,000 | $594,350,000 | $391,565,000 | $549,912,000 |
| Cash And Cash Equivalents | $743,294,000 | $594,350,000 | $391,565,000 | $549,912,000 |
| Accounts Receivable | - | - | - | $0 |
| Debt | ||||
| Total Debt | $77,965,000 | $108,492,000 | $50,672,000 | $51,005,000 |
| Long Term Debt And Capital Lease Obligation | $56,211,000 | $86,272,000 | $44,515,000 | $44,956,000 |
| Long Term Debt | $9,564,000 | $19,022,000 | $1,101,000 | $536,000 |
| Current Debt And Capital Lease Obligation | $21,754,000 | $22,220,000 | $6,157,000 | $6,049,000 |
| Current Debt | $9,091,000 | $8,425,000 | $41,000 | $97,000 |
| Other Current Borrowings | $9,091,000 | $8,425,000 | $41,000 | $97,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $343,265,000 | $413,816,000 | $190,263,000 | $215,482,000 |
| Total Non Current Liabilities Net Minority Interest | $195,558,000 | $226,344,000 | $97,092,000 | $115,217,000 |
| Other Non Current Liabilities | $2,080,000 | $4,732,000 | - | - |
| Non Current Deferred Liabilities | $137,267,000 | $135,340,000 | $52,577,000 | $70,261,000 |
| Non Current Deferred Taxes Liabilities | $23,255,000 | $16,575,000 | $1,339,000 | $0 |
| Current Liabilities | $147,707,000 | $187,472,000 | $93,171,000 | $100,265,000 |
| Current Deferred Liabilities | $37,605,000 | $61,767,000 | $36,426,000 | $56,726,000 |
| Payables And Accrued Expenses | $56,577,000 | $52,632,000 | $27,700,000 | $17,057,000 |
| Payables | $18,118,000 | $21,613,000 | $3,953,000 | $4,586,000 |
| Accounts Payable | $18,118,000 | $21,613,000 | $3,953,000 | $4,586,000 |
| Equity | ||||
| Common Stock Equity | $1,130,865,000 | $1,034,782,000 | $463,436,000 | $485,806,000 |
| Total Equity Gross Minority Interest | $1,130,865,000 | $1,034,782,000 | $463,436,000 | $485,806,000 |
| Stockholders Equity | $1,130,865,000 | $1,034,782,000 | $463,436,000 | $485,806,000 |
| Gains Losses Not Affecting Retained Earnings | $36,717,000 | $-7,637,000 | $0 | $0 |
| Other Equity Adjustments | $36,717,000 | $-7,637,000 | - | - |
| Retained Earnings | $-2,076,002,000 | $-1,431,283,000 | $-967,622,000 | $-639,556,000 |
| Other | ||||
| Ordinary Shares Number | $528,182,693 | $396,802,394 | $234,270,384 | $191,022,864 |
| Share Issued | $528,182,693 | $396,802,394 | $234,270,384 | $191,022,864 |
| Tangible Book Value | $658,804,000 | $550,054,000 | $374,937,000 | $483,699,000 |
| Invested Capital | $1,149,520,000 | $1,062,229,000 | $464,578,000 | $486,439,000 |
| Working Capital | $665,138,000 | $526,797,000 | $344,966,000 | $469,549,000 |
| Capital Lease Obligations | $59,310,000 | $81,045,000 | $49,530,000 | $50,372,000 |
| Total Capitalization | $1,140,429,000 | $1,053,804,000 | $464,537,000 | $486,342,000 |
| Additional Paid In Capital | $3,170,145,000 | $2,473,698,000 | $1,431,056,000 | $1,125,360,000 |
| Capital Stock | $5,000 | $4,000 | $2,000 | $2,000 |
| Common Stock | $5,000 | $4,000 | $2,000 | $2,000 |
| Non Current Deferred Revenue | $114,012,000 | $118,765,000 | $51,238,000 | $70,261,000 |
| Long Term Capital Lease Obligation | $46,647,000 | $67,250,000 | $43,414,000 | $44,420,000 |
| Current Deferred Revenue | $37,605,000 | $61,767,000 | $36,426,000 | $56,726,000 |
| Current Capital Lease Obligation | $12,663,000 | $13,795,000 | $6,116,000 | $5,952,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $31,771,000 | $50,853,000 | $22,888,000 | $20,433,000 |
| Current Accrued Expenses | $38,459,000 | $31,019,000 | $23,747,000 | $12,471,000 |
| Goodwill | $162,158,000 | $148,873,000 | $52,056,000 | $801,000 |
| Net PPE | $169,480,000 | $233,213,000 | $120,173,000 | $121,447,000 |
| Accumulated Depreciation | $-89,214,000 | $-62,671,000 | $-44,872,000 | $-30,115,000 |
| Gross PPE | $258,694,000 | $295,884,000 | $165,045,000 | $151,562,000 |
| Leases | $70,778,000 | $72,727,000 | $45,929,000 | $41,872,000 |
| Construction In Progress | $511,000 | $2,714,000 | $3,231,000 | $8,747,000 |
| Other Properties | $158,713,000 | $193,078,000 | $93,759,000 | $80,779,000 |
| Machinery Furniture Equipment | $28,692,000 | $27,365,000 | $22,126,000 | $20,164,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | - | - | - | $0 |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-380,435,000 | $-376,219,000 | $-300,332,000 | $-120,883,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-371,808,000 | $-359,174,000 | $-287,780,000 | $-83,524,000 |
| Cash Flow From Continuing Operating Activities | $-371,808,000 | $-359,174,000 | $-287,780,000 | $-83,524,000 |
| Operating Gains Losses | $4,502,000 | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-8,627,000 | $-17,045,000 | $-12,552,000 | $-37,359,000 |
| Investing Cash Flow | $-16,871,000 | $260,059,000 | $-10,228,000 | $193,249,000 |
| Cash Flow From Continuing Investing Activities | $-16,871,000 | $260,059,000 | $-10,228,000 | $193,249,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $528,864,000 | $300,417,000 | $128,093,000 | $143,711,000 |
| Financing Cash Flow | $521,532,000 | $304,120,000 | $140,133,000 | $154,345,000 |
| Cash Flow From Continuing Financing Activities | $521,532,000 | $304,120,000 | $140,133,000 | $154,345,000 |
| Net Other Financing Charges | $-3,000,000 | - | - | - |
| Net Common Stock Issuance | $528,864,000 | $300,417,000 | $128,093,000 | $143,711,000 |
| Common Stock Issuance | $528,864,000 | $300,417,000 | $128,093,000 | $143,711,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-8,425,000 | $-4,440,000 | $-766,000 | $-90,000 |
| End Cash Position | $753,921,000 | $603,024,000 | $401,425,000 | $559,112,000 |
| Beginning Cash Position | $603,024,000 | $401,425,000 | $559,112,000 | $295,349,000 |
| Effect Of Exchange Rate Changes | $18,044,000 | $-3,406,000 | $188,000 | $-307,000 |
| Changes In Cash | $132,853,000 | $205,005,000 | $-157,875,000 | $264,070,000 |
| Proceeds From Stock Option Exercised | $4,093,000 | $8,143,000 | $12,806,000 | $10,724,000 |
| Net Issuance Payments Of Debt | $-8,425,000 | $-4,440,000 | $-766,000 | $-90,000 |
| Net Long Term Debt Issuance | $-8,425,000 | $-4,440,000 | $-766,000 | $-90,000 |
| Long Term Debt Payments | $-8,425,000 | $-4,440,000 | $-766,000 | $-90,000 |
| Net Investment Purchase And Sale | $-3,806,000 | $0 | $480,000 | $230,608,000 |
| Sale Of Investment | $0 | $0 | $480,000 | $230,608,000 |
| Purchase Of Investment | $-3,806,000 | $0 | $0 | $0 |
| Net Business Purchase And Sale | $-4,438,000 | $277,104,000 | $1,844,000 | $0 |
| Sale Of Business | $0 | $277,104,000 | $1,844,000 | $0 |
| Purchase Of Business | $-4,438,000 | $0 | $0 | $0 |
| Net Intangibles Purchase And Sale | $-2,158,000 | $-3,350,000 | $-597,000 | $-300,000 |
| Purchase Of Intangibles | $-2,158,000 | $-3,350,000 | $-597,000 | $-300,000 |
| Net PPE Purchase And Sale | $-6,469,000 | $-13,695,000 | $-11,955,000 | $-37,059,000 |
| Purchase Of PPE | $-6,469,000 | $-13,695,000 | $-11,955,000 | $-37,059,000 |
| Change In Working Capital | $13,688,000 | $-46,758,000 | $-44,257,000 | $104,921,000 |
| Change In Other Working Capital | $-36,771,000 | $-28,038,000 | $-41,076,000 | $110,320,000 |
| Change In Other Current Liabilities | $-19,988,000 | $-15,582,000 | $-9,862,000 | $-7,110,000 |
| Change In Payables And Accrued Expense | $-12,351,000 | $11,690,000 | $8,437,000 | $1,713,000 |
| Change In Accrued Expense | $-9,735,000 | $5,255,000 | $9,424,000 | $-54,000 |
| Change In Payable | $-2,616,000 | $6,435,000 | $-987,000 | $1,767,000 |
| Change In Account Payable | $-2,616,000 | $6,435,000 | $-987,000 | $1,767,000 |
| Change In Prepaid Assets | $49,859,000 | $-8,757,000 | $6,000,000 | - |
| Change In Receivables | $32,939,000 | $-6,071,000 | $-7,756,000 | $-2,000 |
| Other Non Cash Items | $53,881,000 | $32,955,000 | $5,450,000 | $8,560,000 |
| Stock Based Compensation | $111,223,000 | $81,688,000 | $53,503,000 | $27,909,000 |
| Asset Impairment Charge | $5,956,000 | $108,000 | $1,188,000 | $2,806,000 |
| Depreciation Amortization Depletion | $83,701,000 | $36,494,000 | $24,402,000 | $11,756,000 |
| Depreciation And Amortization | $83,701,000 | $36,494,000 | $24,402,000 | $11,756,000 |
| Gain Loss On Sale Of Business | $4,502,000 | $0 | $0 | - |
| Net Income From Continuing Operations | $-644,759,000 | $-463,661,000 | $-328,066,000 | $-239,476,000 |
| Interest Paid Supplemental Data | - | - | $96,000 | $55,000 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Changes In Account Receivables | - | - | - | - |
Fetched: 2026-06-18